These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Paddock S; Laje G; Charney D; Rush AJ; Wilson AF; Sorant AJ; Lipsky R; Wisniewski SR; Manji H; McMahon FJ Am J Psychiatry; 2007 Aug; 164(8):1181-8. PubMed ID: 17671280 [TBL] [Abstract][Full Text] [Related]
4. The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Lekman M; Laje G; Charney D; Rush AJ; Wilson AF; Sorant AJ; Lipsky R; Wisniewski SR; Manji H; McMahon FJ; Paddock S Biol Psychiatry; 2008 Jun; 63(12):1103-10. PubMed ID: 18191112 [TBL] [Abstract][Full Text] [Related]
5. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Shiroma PR; Drews MS; Geske JR; Mrazek DA Am J Geriatr Psychiatry; 2014 Nov; 22(11):1140-8. PubMed ID: 23973251 [TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics with antidepressants in the STAR*D study. Lin E; Chen PS Pharmacogenomics; 2008 Jul; 9(7):935-46. PubMed ID: 18597655 [TBL] [Abstract][Full Text] [Related]
7. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Perlis RH; Purcell S; Fava M; Fagerness J; Rush AJ; Trivedi MH; Smoller JW Arch Gen Psychiatry; 2007 Jun; 64(6):689-97. PubMed ID: 17548750 [TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Horstmann S; Lucae S; Menke A; Hennings JM; Ising M; Roeske D; Müller-Myhsok B; Holsboer F; Binder EB Neuropsychopharmacology; 2010 Feb; 35(3):727-40. PubMed ID: 19924111 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics in major depression: a comprehensive meta-analysis. Niitsu T; Fabbri C; Bentini F; Serretti A Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():183-94. PubMed ID: 23733030 [TBL] [Abstract][Full Text] [Related]
10. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. ; ; Am J Psychiatry; 2013 Feb; 170(2):207-17. PubMed ID: 23377640 [TBL] [Abstract][Full Text] [Related]
11. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Ising M; Lucae S; Binder EB; Bettecken T; Uhr M; Ripke S; Kohli MA; Hennings JM; Horstmann S; Kloiber S; Menke A; Bondy B; Rupprecht R; Domschke K; Baune BT; Arolt V; Rush AJ; Holsboer F; Müller-Myhsok B Arch Gen Psychiatry; 2009 Sep; 66(9):966-975. PubMed ID: 19736353 [TBL] [Abstract][Full Text] [Related]
12. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Helton SG; Lohoff FW Pharmacogenomics; 2015; 16(5):541-53. PubMed ID: 25916524 [TBL] [Abstract][Full Text] [Related]
13. Genetic studies of drug response and side effects in the STAR*D study, part 2. Garriock HA; Hamilton SP J Clin Psychiatry; 2009 Sep; 70(9):1323-5. PubMed ID: 19818256 [No Abstract] [Full Text] [Related]
14. Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. Kelley ME; Dunlop BW; Nemeroff CB; Lori A; Carrillo-Roa T; Binder EB; Kutner MH; Rivera VA; Craighead WE; Mayberg HS Depress Anxiety; 2018 Oct; 35(10):992-1000. PubMed ID: 30260539 [TBL] [Abstract][Full Text] [Related]